November 3, 2015 / 12:07 PM / 2 years ago

GSK aims to file up to 20 new drugs for approval by 2020

LONDON, Nov 3 (Reuters) - GlaxoSmithKline said on Tuesday it had the potential to file up to 20 new drugs for approval before 2020 as it seeks to revitalise a portfolio hit by falling sales of best-selling inhaled lung treatment Advair.

Britain’s biggest drugmaker is trying to boost low investor expectations for its product pipeline by hosting its first research and development day in more than a decade.

The company highlighted advanced and early-stage projects in respiratory medicine, immunology, oncology, vaccines, HIV and other infections, and rare diseases.

Reporting by Ben Hirschler; Editing by Keith Weir

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below